Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


North West Fund for Biomedical leads Cytox’s £1.5mm Series B financing

Executive Summary

Spark Impact affiliate North West Fund for Biomedical led a £1.5mm ($2.5mm) Series B financing for Cytox Ltd. (blood testing to assess risk for cognitive decline, Alzheimer’s disease, and other forms of dementia). First-time backer Seneca Partners joined along with Wren Capital, the Rainbow Seed Fund (managed by Midven), private investors, and other existing shareholders. The company will use the funding to extend the clinical research program initiated a month ago to study mTOR dysregulation biomarkers (mTOR signaling is thought to be altered in Alzheimer’s).
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies